Abstract
INTRODUCTION
Tuberculosis, one of the most common infections, is caused by Mycobacterium tuberculosis. According to the World Health Organization (WHO), nearly one third of the world's population has been exposed to the tuberculosis pathogen [1] . Annually, 8 million people become ill with tuberculosis and 2 million people die from the disease worldwide. Every 15 seconds, someone dies of tuberculosis [2] . There are a number of known factors that make people more susceptible to tuberculosis infection worldwide, the most important of which is human immunodeficiency virus (HIV). The association of tuberculosis with HIV infection is so dramatic that in some cases, nearly twothird of the patients diagnosed with the tuberculosis are also HIV-1 seropositive [3] . Smoking more than 20 cigarettes a day also increases the risk of tuberculosis by two-to four times [4] .
Following the discovery of isoniazid, there have been no new classes of antitubercular drugs in past 40 years [5] . Moreover, there has been a recent and disturbing increase in the number of tubercular cases that are caused by organisms which are resistant to the first-line drugs such as isoniazid, rifampicin, ethambutol, streptomycin and pyrazinamide [6] . The Global Alliance for Tuberculosis (GATB) drug development was established to address this need [7] . Its top priority is the development of a new agent that will shorten the duration of chemotherapy from the current 6 -8 months to two months or less. Also new drugs with activity against mycobacterium drug-resistant tuberculosis and latent tuberculosis are needed.
The addition of a beta-lactamase inhibitor to amoxicillin greatly improves its in vitro activity against M. tuberculosis [8] . Gallic acid is a naturally existing antioxidant [9] which occurs along with tannins in most plant species. It possesses various biological activities such as analgesic [10] , antimicrobial [11] , antineoplastic [12] and antityrosinase [13] .
Azetidinone is chemically 2-Azacyclobutanone which is an integral part of penicillin.
Ezetimibe, an azetidinone, represents the first new approach to lipid lowering therapy in more than a decade [14] . Moreover, this heterocycle is associated with muscle relaxant [15] , antitubercular [16] and antiinflammatory [17] activities. Considering the above pharmacological activities of both gallic acid and azetidinones we thought that it would be worthwhile to incorporate the azetidinone ring into gallic acid to have synergestic effect.
EXPERIMENTAL Equipment
Reactions were monitored by thin layer chromatography (TLC) on precoated silica gel plates obtained from E. Merck and Co. Melting points were determined using Veego digital melting point apparatus and are uncorrected. IR spectra were recorded on a Perkin Elmer FTIR Spectrometer. 
Methods
All the compounds were synthesized according to the scheme shown in Figure 1 . The purity of the compounds was determined on TLC plates using silica gel G as a stationary phase and iodine vapors as visualizing agent.
Synthesis of 3,4,5-trihydroxy benzoic acid hydrazide from propyl gallate (1a)
Propyl gallate (0.01 mol) in ethanol and hydrazine hydrate (0.01 mol) were refluxed for 6 h. The excess of solvent was distilled off under reduced pressure using a vacuum pump. The cold residual mass was washed with distilled water, filtered and dried. 
General procedure for Synthesis 4-Aryl-3-chloro-N-(3,4,5-trihydroxy benzamido)-2-azetidinones (3a-o)
A mixture of Schiff base (0.002 mol) and triethyl amine (0.004 mol) were dissolved in 1,4-Dioxan (50 ml). To this, well stirred cold solution of chloroacetyl chloride (0.004 mol) was added drop wise for 20 min, then stirred for further 3 h and left at room temperature for 48 h [18] . The resultant mixture was concentrated, cooled and then poured into ice cold water filtered off, dried and recrystalised from methanol. ). (3R, 4S)-3-Chloro-4-(2-hydroxy phenyl)-N-(-3,4,5 
(3R, 4S)-3-Chloro-4-(phenyl)-N-(-3,4,5-trihydroxy benzamido)-2-azetidinone (3a):

Evaluation of antimicrobial activity
The minimum inhibitory concentration (MIC) of the test compounds was determined by broth dilution method [19, 20] . Each of the test compounds and the standard drugs were dissolved in DMSO at a concentration of 100 µg/ml. Further dilutions of the test compounds and standards in the test medium were prepared at concentrations of 50, 25, 12. 
Evaluation of anti-tubercular activity
Antitubercular activity was evaluated against Mycobacterium tuberculosis H37 Rv using Microplate alamar blue assay (MABA) method [21, 22] . Antitubercular susceptibility test was performed in black, clear-bottomed, 96-well microplates (Packard Instrument Company, Meriden, Conn., USA) in order to minimize background fluorescence. Initial drug dilutions were prepared in dimethylsulfoxide and subsequent two-fold dilutions were performed in 0.1 ml of 7H9GC media in the microplates. An aliquot (100 µl) of 2000CFU/ml of M. tuberculosis H37 Rv were added to each well of 96-well microtitre plate containing test compounds. Three control well plates containing drug and medium, bacteria and medium, and medium only were also prepared. All microtitre plates were incubated at 37 °C for seven days. At day 7 of incubation, Alamar Blue dye solution (20 µl Alamar Blue solution and 12.5 ml of 20 % Tween 80) was added to all the wells and the plates re-incubated at 37 °C for 24 h. Fluorescence was measured in a Victor II multilabel fluorometer (Perkin Elmer Life Sciences Inc., Boston, MA, USA) and MIC was determined.
Statistical anlaysis
The antimicrobial study was a completely randomized study with three replications. Data were subjected to ANOVA using GraphPad Instat (Version 3.01, University of Kentucky, GTA-50429-259). A significant difference at p < 0.01 was set for the antimicrobial studies.
RESULTS
Physicochemical
parameters of the synthesized compounds, including color, R f value, and melting point are shown in Table 1 while antimicrobial and antitubercular results are listed in Table 2 .
Antimicrobial activity
Compounds 3f, 3g, 3k and 3o were active, among the compounds in the series (3a-o), exhibiting antibacterial and antifungal activities as high as those of the reference standards -ciprofloxacin and ketoconazole, respectively. On the other hand, compounds 3a, 3c, 3h, 3i and 3j exhibited moderate activity.
Antitubercular activity
Compounds 3f, 3g, 3k and 3o showed MIC values equivalent to that of the reference standard, isoniazid. Compounds 3a, 3c, 3j 
DISCUSSION
The monocyclic 2-azetidinones, carbapenams and monobactams are active only against Gram-negative bacteria [23] . The synthesized compounds, however, showed about the same level of activity against both Gram-positive and Gram-negative bacteria.
The results of antimicrobial activity and antitubercular activity revealed that compounds 3f, 3g, and 3o which have chloro substitution (electron withdrawing group) and 3k which has para dimethyl amino (bulkier group) enhanced the activity of the azetidinones while the other groups, such as hydroxy, methoxy and nitro groups did not influence the activity. Among the chloro substituted compounds (3f, 3g, and 3o) compound 3g, which has a chloro group at meta position, exhibited the highest activity in the series. This suggests that electron withdrawing groups and bulkier groups are responsible for the activity. It is interesting to note that some of the currently used antitubercular drugs, such as pyrazinamide, isoniazid and ethionamide, also possess electron withdrawing groups as its pharmacophore. Further studies are going on in our laboratory to establish the quantitative structure activity relationship (QSAR) of the series.
CONCLUSION
This study indicates that the antimicrobial and antitubercular activities of the synthesized compounds can be attributed to the presence of 2-Cl, 3-Cl, 4-Cl and 4-N-(CH 3 ) 2 in phenyl ring at the fourth position of the azetidinone nucleus. The findings of this work should be helpful to medicinal chemists involved in further drug development in this field.
